Hot Topics

Poll

Why is it a big mistake to link funding of R&D costs with drug prices?:

Civil Society comments on USPTO humanitarian priority review voucher proposal

On November 19, 2010, Knowledge Ecology International, Medecins Sans Frontieres/Doctors without Borders, Oxfam America and Public Citizen answered a Request for Comments from the US Department of Commerce on a proposal to "Incentivize Humanitarian Technologies and Licensing Through the Intellectual Property System".

Notes from EU Parliament meeting on innovation+access for medical technologies

Today I am attending a meeting at the European Parliament on new models of innovation for medical technologies. The event was organized by three MEPs, Thijs Berman, Eva Joly and Carl Schlyter, in collaboration with the European Parliament Working Group on Innovation, Access to Medicines and Poverity-Related Diseaes, and several consumer rights, public health and development NGOs (TACD, Health Action International, KEI, Oxfam and IQsensato).

Non-responsive letter from David Kappos of USPTO to Senators Sanders and Brown regarding ACTA consistency with US law

In a October 19, 2010, Senators Bernard Sanders (I-VT) and Sherrod Brown (D-OH) wrote to David Kappos, the Director of the USPTO, asking for an assessment of conflicts between the October 2010 ACTA text, and U.S. law. (attached here).

Kappos-200.jpg
Undersecretary of Commerce for
Intellectual Property, David Kappos

A KEI note to Library of Congress about ACTA text

From: James Love
To: Michele Woods
Cc: Nancy Weiss
Subject: Some examples of US inconsistency with ACTA
Date: Fri, 12 Nov 2010 07:29:09 -0500

This note cites several areas where US law is plainly inconsistent with
ACTA.

In addition, in a separate analysis,I have called attention to proposed
legislation in USA on orphan copyrighted works that are very
inconsistent with ACTA provisions on remedies.
http://www.keionline.org/node/980

Some examples of inconsistencies between ACTA and US law

The November 15, 2010 version of ACTA

The final conclusions for WIPO SCCR 21

Sometime very early Saturday morning, SCCR 21 ended with these conclusions.

Communication to SCCR delegates regarding the beneficiaries of a new WIPO treaty for copyright exceptions for disabilities

Information note to SCCR delegates on the scope of disabilities in a new WIPO treaty

12 November 2010

The delegates to the SCCR are considering various proposals to deal with expanded access to copyrighted works by persons who are blind or who have other disabilities.

The proposal sponsored by Brazil, Ecuador, Mexico and Paraguay would extend the benefits of the treaty, not only to persons who are blind or visually impaired, but also as follows:

KEI statement at SCCR 21

This was our 400 word statement at the WIPO SCCR 21.

Statement of KEI at WIPO SCCR 21, November 11, 2010

There should be a compelling rationale for creating new global norms for copyrights.

KEI opposes work on a new broadcasting treaty, and supports work on performers treaty.

KEI supports work at the SCCR on new possible norms for copyright limitations and exceptions, particularly as regards to access to knowledge, and uses of new technologies.

WIPO SCCR21: Group B proposal on a work program for Copyright exceptions and limitations

Today, Wednesday November 10 2010, during the 3rd day of the WIPO SCCR21, the Group B presented a proposal for a Work Program on copyright exceptions and limitations for the WIPO SCCR. Group B is the negotiation group that groups developed countries like US, EU, Switzerland and others.

The proposal is available here

SCCR21: Proposal for the consideration of the African Group on a Decision on SCCR

The following proposal for a road map for the SCCR's consideration of limitations and exceptions was submitted by the African Group on Tuesday, 9 November 2010.

Proposal for the consideration of the African Group on a Decision on SCCR

(Limitations and exceptions)

Bearing in mind

  • the Development Agenda recommendations;

SAVE THE DATE (10 November 2010): What should the WIPO SCCR do about limitations & exceptions: the way forward?

On 10 November 2010, Knowledge Ecology International will hold a side event from 13:30 to 14:45 in the Uchtenhagen room at WIPO which shall address the question, "What should the WIPO SCCR do about limitations & exceptions: the way forward"? Speakers include representatives from the Centre for Internet & Society, Egypt, the International Publishers Association, KEI and the South Centre. This is an open event. Please see below for details.

What should the WIPO SCCR do about limitations & exceptions: the way forward?

Invitation to the KEI side bar event

Six recent secret ACTA documents

SCCR 21: General statement of Group B (covering broadcasting, AV protection and limitations and exceptions)

The following general statement was delivered by France, on behalf of Group B, on the first day (8 November 2010) of SCCR 21.

SCCR 21
Group B opening statement

I thank you M. Chair,

Group B is glad to welcome you back in Geneva for this 21st session of the Standing Committee on Copyright and Related Rights, which we hope will be a productive one.

SCCR 21: Initial impressions from day 1

The 21st session of the WIPO Standing Committee on Copyright and Related Rights (SCCR) commenced its work at 10:33 AM on Monday, 8 November 2010.

This unusually quick start is perhaps indicative of Member States' commitment to examine the three substantive agenda items up for consideration during this five day negotiation; these three issues include: 1) protection of broadcasting organizations, 2) protection of audiovisual performances and 3) limitations and exceptions.

Global Fund calls upon drug companies to "share without delay" AIDS drug patents with the Medicines Patent Pool

In a October 7, 2010 letter, Professor Michel Kazatchkine, the Executive Director of the Global Fund to fight AIDS, Tuberculosis and Malaria, has written to Dr. Jorge Bermudez, the UNITAID Executive Director, to discuss the Medicines Patent Pool.

Kazatchkine congratulates UNITAID for the announcement that an agreement had been reached between U.S. National Institute for Health and the Medicines Patent Pool for the voluntary license of the NIH patents rights on an HIV-AID drug, Darunavir.

Syndicate content